Reports

Drug name	NICE TAs	Comments
Nalmefene	TA325 - Nalmefene for reducing alcohol consumption in people with alcohol dependence	Restricted to specialist substance misuse services
Naloxegol (Moventig®)	TA345 - Naloxegol for treating opioid-induced constipation	For treating opioid-induced chronic constipation - use in line with NICE
Naltrexone tablets	TA115 - Naltrexone for the management of opioid dependence
Natalizumab injection	TA127 - Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis	For hospital use only
Nemolizumab (Nemluvio®)	NICE TA 1077 Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over
Nilotinib capsules	TA251 - Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia TA241 - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
Nintedanib	TA379 - Nintedanib for treating idiopathic pulmonary fibrosis TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases TA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
Nintedanib#8.1	TA347 - Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
Niraparib	TA528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer TA673 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Nirmatrelvir plus ritonavir (Paxlovid®)	TA878 - Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports